^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Myelodysplastic Syndrome

    18h
    AN-CNA: Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS (clinicaltrials.gov)
    P=N/A, N=323, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    19h
    Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IFNG (Interferon, gamma)
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan
    1d
    Assessing the Frequency of VEXAS-Related Canonical UBA1 Mutations in Myelodysplastic Syndrome Patients. (PubMed, Eur J Haematol)
    Expanding the sample size and using targeted NGS or ddPCR would improve mutation detection sensitivity and could reveal UBA1 canonical and non-canonical variants and more accurately estimate the frequency of VEXAS-related mutations in the MDS population.
    Journal
    |
    NLRP3 (NLR Family Pyrin Domain Containing 3)
    2d
    A single-cell solution to a transplant mystery. (PubMed, Med)
    Conventional diagnostics could not determine whether the mutant clone was donor- or recipient-derived. Combining transcriptome profiling with targeted U2AF1 enrichment pinpointed the clone's origin and guided a second transplant, leading to remission.
    Journal
    |
    U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    3d
    SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, The First Affiliated Hospital of Soochow University
    New P2 trial
    |
    cytarabine • azacitidine • cyclophosphamide • zeprumetostat (SHR-2554)
    3d
    A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=10, Terminated, University of Michigan Rogel Cancer Center | N=20 --> 10 | Trial completion date: Jul 2026 --> Aug 2025 | Suspended --> Terminated | Trial primary completion date: Jul 2026 --> Aug 2025; Interim Analysis per Protocol
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Venclexta (venetoclax) • cytarabine • fludarabine IV
    3d
    Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    4d
    A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms (clinicaltrials.gov)
    P1, N=64, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=115 --> 64
    Enrollment closed • Enrollment change • First-in-human
    4d
    Clinical characteristics and prognostic analysis of acute erythroid leukemia (PubMed, Zhonghua Nei Ke Za Zhi)
    Survival differed significantly among the three etiological groups (χ2=11.53, P=0.003). AEL is a subtype of acute myeloid leukemia with extremely poor prognosis that is highly associated with TP53 gene abnormalities.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    5d
    PREeMPT: A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant (clinicaltrials.gov)
    P2, N=450, Not yet recruiting, Medical College of Wisconsin
    New P2 trial
    5d
    A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies (clinicaltrials.gov)
    P1, N=280, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial • First-in-human
    5d
    Phase 1 Dose Escalation Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Laguna Biotherapeutics, Inc.
    New P1 trial • First-in-human